IRCT20170609034406N11招募中3 期
Effect of Dapagliflozin in The Prevention of Acute Kidney Injury Caused by Iodinated Contrast Media: A Randomized Placebo-Controlled Clinical Trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Adults aged 18 years or older
- •Patients who are candidates for CT scan and receive Iodized Contrast Agents
排除标准
- •Patients with underlying renal failure with GFR less than 30
- •Patients with liver failure (Child-Pugh stage B and C)
- •Patients with heart failure
- •Pregnant and lactating women
- •The presence of chronic infection or autoimmune diseases
- •History of taking Dapagliflozin
- •Diabetic patients with Diabetic foot ulcers
- •Patients are susceptible to ketoacidosis
- •Alcoholic patients
- •Patients with pancreatic failure
- •History of allergy to Dapagliflozin
- •Patients with osteoporosis
- •Concomitant use of nephrotoxic drugs such as Calcineurin Inhibitors , Aminoglycosides, Vancomycin, Amphotericin B
- •Participation in other clinical studuies
研究者
相似试验
招募中
3 期
The efficacy of dapagliflozin in preventing contrast-associated acute kidney injuryAcute Coronary Syndrome.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarctionIRCT20181026041471N1Rajaie Cardiovascular Medical and Research Institute1,500
尚未招募
不适用
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003897-41-DKAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-BGAstraZeneca AB4,500